TAKARA BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,086 JPY | -1.18% |
|
+5.95% | -13.26% |
| 10/05 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
| 18/03 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,09,107 | 2,68,647 | 3,57,394 | 2,69,851 | 2,08,680 | 1,30,771 | - | - |
| Enterprise Value (EV) 1 | 2,90,074 | 2,49,501 | 3,32,542 | 2,47,265 | 1,57,805 | 1,16,803 | 1,30,771 | 1,30,771 |
| P/E ratio | 84.5 x | 70.3 x | 37.4 x | 13.6 x | 13 x | 78.9 x | 37.4 x | 31.2 x |
| Yield | 0.27% | 0.36% | 0.54% | 1.47% | 2.42% | 1.75% | 1.66% | 1.84% |
| Capitalization / Revenue | 8.62 x | 7.77 x | 7.75 x | 3.99 x | 2.67 x | 2.68 x | 2.79 x | 2.56 x |
| EV / Revenue | 8.62 x | 7.77 x | 7.75 x | 3.99 x | 2.67 x | 2.68 x | 2.79 x | 2.56 x |
| EV / EBITDA | 35.7 x | 27.7 x | 20.2 x | 8.19 x | 8.28 x | 14.7 x | 15.2 x | 12.9 x |
| EV / FCF | 1,493 x | 114 x | 35.2 x | -3,138 x | 6.91 x | -18.9 x | 16.3 x | 79.6 x |
| FCF Yield | 0.07% | 0.88% | 2.84% | -0.03% | 14.5% | -5.29% | 6.12% | 1.26% |
| Price to Book | 4.83 x | 4.04 x | 4.82 x | 2.81 x | 1.86 x | 1.05 x | 1.17 x | 1.15 x |
| Nbr of stocks (in thousands) | 1,20,416 | 1,20,416 | 1,20,416 | 1,20,416 | 1,20,416 | 1,20,416 | - | - |
| Reference price 2 | 2,567 | 2,231 | 2,968 | 2,241 | 1,733 | 1,086 | 1,086 | 1,086 |
| Announcement Date | 14/05/19 | 14/05/20 | 13/05/21 | 12/05/22 | 11/05/23 | 10/05/24 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 35,841 | 34,565 | 46,086 | 67,699 | 78,142 | 43,505 | 46,918 | 51,013 |
| EBITDA 1 | 8,656 | 9,691 | 17,658 | 32,956 | 25,190 | 7,922 | 8,611 | 10,147 |
| EBIT 1 | 5,463 | 6,274 | 13,952 | 28,902 | 20,541 | 3,003 | 4,838 | 5,781 |
| Operating Margin | 15.24% | 18.15% | 30.27% | 42.69% | 26.29% | 6.9% | 10.31% | 11.33% |
| Earnings before Tax (EBT) 1 | 4,823 | 5,433 | 13,552 | 27,532 | 21,224 | 2,853 | 4,802 | 5,831 |
| Net income 1 | 3,657 | 3,819 | 9,547 | 19,849 | 16,012 | 1,480 | 3,493 | 4,186 |
| Net margin | 10.2% | 11.05% | 20.72% | 29.32% | 20.49% | 3.4% | 7.45% | 8.21% |
| EPS 2 | 30.38 | 31.72 | 79.29 | 164.8 | 133.0 | 12.30 | 29.01 | 34.76 |
| Free Cash Flow 1 | 207 | 2,356 | 10,165 | -86 | 30,204 | -6,914 | 8,006 | 1,642 |
| FCF margin | 0.58% | 6.82% | 22.06% | -0.13% | 38.65% | -15.43% | 17.06% | 3.22% |
| FCF Conversion (EBITDA) | 2.39% | 24.31% | 57.57% | - | 119.9% | - | 92.97% | 16.19% |
| FCF Conversion (Net income) | 5.66% | 61.69% | 106.47% | - | 188.63% | - | 229.18% | 39.24% |
| Dividend per Share 2 | 7.000 | 8.000 | 16.00 | 33.00 | 42.00 | 17.00 | 18.00 | 20.00 |
| Announcement Date | 14/05/19 | 14/05/20 | 13/05/21 | 12/05/22 | 11/05/23 | 10/05/24 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16,450 | 18,115 | 17,393 | 28,693 | 16,279 | 31,551 | 14,108 | 22,040 | 36,148 | 14,102 | 18,485 | 32,587 | 27,619 | 17,936 | 45,555 | 9,176 | 9,940 | 19,116 | 10,618 | 13,771 | 24,389 | 9,594 | 10,274 | 19,868 | 11,323 | 15,231 | 26,553 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 3,035 | 3,239 | 3,736 | - | 5,601 | 14,105 | 5,821 | 8,976 | 14,797 | 4,537 | 6,333 | 10,870 | 8,533 | 1,138 | 9,671 | 423 | 987 | 1,410 | -1,074 | 2,667 | 1,593 | -175 | 819 | 644 | 913 | 2,586 | 3,499 |
| Operating Margin | 18.45% | 17.88% | 21.48% | - | 34.41% | 44.71% | 41.26% | 40.73% | 40.93% | 32.17% | 34.26% | 33.36% | 30.9% | 6.34% | 21.23% | 4.61% | 9.93% | 7.38% | -10.11% | 19.37% | 6.53% | -1.82% | 7.97% | 3.24% | 8.06% | 16.98% | 13.18% |
| Earnings before Tax (EBT) 1 | 2,950 | 2,483 | 3,281 | - | 5,642 | 14,203 | 5,911 | 7,418 | 13,329 | 5,479 | 6,352 | 11,831 | 8,487 | 906 | 9,393 | 505 | 1,083 | 1,588 | -1,088 | 2,353 | 1,265 | -259 | 734 | 475 | 822 | 2,519 | 3,341 |
| Net income 1 | 2,075 | 1,744 | 2,274 | - | 3,984 | 10,009 | 4,355 | 5,485 | 9,840 | 3,907 | 4,631 | 8,538 | 6,057 | 1,417 | 7,474 | 319 | 765 | 1,084 | -930 | 1,326 | 396 | -539 | 454 | -85 | 542 | 2,239 | 2,781 |
| Net margin | 12.61% | 9.63% | 13.07% | - | 24.47% | 31.72% | 30.87% | 24.89% | 27.22% | 27.71% | 25.05% | 26.2% | 21.93% | 7.9% | 16.41% | 3.48% | 7.7% | 5.67% | -8.76% | 9.63% | 1.62% | -5.62% | 4.42% | -0.43% | 4.79% | 14.7% | 10.47% |
| EPS 2 | 17.23 | 14.49 | 18.89 | - | 33.08 | 83.12 | 36.17 | 45.55 | 81.72 | 32.45 | 38.46 | 70.91 | 50.30 | 11.76 | 62.06 | 2.650 | 6.350 | 9.000 | -7.720 | 11.02 | 3.300 | -4.500 | 3.800 | -0.7000 | 4.500 | 18.60 | 23.10 |
| Dividend per Share 2 | - | 8.000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00 | 12.00 | - | - | - | - | - | 17.00 |
| Announcement Date | 12/11/19 | 14/05/20 | 10/11/20 | 13/05/21 | 09/11/21 | 09/11/21 | 10/02/22 | 12/05/22 | 12/05/22 | 04/08/22 | 10/11/22 | 10/11/22 | 09/02/23 | 11/05/23 | 11/05/23 | 08/08/23 | 09/11/23 | 09/11/23 | 14/02/24 | 10/05/24 | 10/05/24 | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 19,033 | 19,146 | 24,852 | 22,586 | 50,875 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 207 | 2,356 | 10,165 | -86 | 30,204 | -6,914 | 8,006 | 1,643 |
| ROE (net income / shareholders' equity) | 5.8% | 5.9% | 13.6% | 23.3% | 15.4% | 1.3% | 3.15% | 3.58% |
| ROA (Net income/ Total Assets) | 8.1% | 8.69% | 17.2% | 27.7% | 16.9% | 2.72% | 5% | - |
| Assets 1 | 45,154 | 43,939 | 55,546 | 71,651 | 94,806 | 54,431 | 69,867 | - |
| Book Value Per Share 2 | 532.0 | 552.0 | 616.0 | 796.0 | 932.0 | 926.0 | 930.0 | 941.0 |
| Cash Flow per Share 2 | 54.20 | 56.90 | 107.0 | 195.0 | 167.0 | 48.70 | 77.40 | 86.60 |
| Capex 1 | 6,002 | 3,983 | 8,673 | 12,356 | 5,747 | 14,500 | 10,000 | 6,000 |
| Capex / Sales | 16.75% | 11.52% | 18.82% | 18.25% | 7.35% | 32.35% | 21.31% | 11.76% |
| Announcement Date | 14/05/19 | 14/05/20 | 13/05/21 | 12/05/22 | 11/05/23 | 10/05/24 | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,086
JPY
Average target price
1,567
JPY
Spread / Average Target
+44.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.26% | 85Cr | |
| +33.63% | 5.08TCr | |
| -0.09% | 4.28TCr | |
| +49.62% | 4.2TCr | |
| -4.96% | 2.95TCr | |
| +11.18% | 2.61TCr | |
| -21.95% | 1.91TCr | |
| +8.61% | 1.31TCr | |
| +28.31% | 1.22TCr | |
| +24.73% | 1.21TCr |
- Stock Market
- Equities
- 4974 Stock
- Financials Takara Bio Inc.